Seeking Alpha
20 Jul 2026, 19:19 UTC · 11h ago
Scribe Therapeutics Starts IPO Effort For CRISPR Pipeline Development
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
20 Jul 2026, 19:19 UTC · 11h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Scribe Therapeutics' lead candidate, STX-1150, demonstrated >50% LDL-C reduction in nonhuman primates. — Strong preclinical efficacy in a primary biomarker for cardiovascular disease is a major positive catalyst for biotech valuation.
+0.60First human data for STX-1150 is not expected until H1 2027. — The long timeframe until clinical validation creates a significant data vacuum and increases the duration of capital risk.
-0.40The company is backed by strategic partners Eli Lilly and Andreessen Horowitz and co-founded by Nobel Laureate Jennifer Doudna. — High-profile backing and scientific pedigree reduce execution risk and increase the likelihood of future M&A or funding.
+0.30Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
Mentioned as a strong backer of an innovative gene-editing company, though no direct financial impact is stated.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
2d ago
